Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

This content is for healthcare professionals only.

Please confirm you are a healthcare professional.

Yes
No
iwNHL 2020 Session IV

Novel Therapies Part II

Presentations
Novel BTK inhibitors: how to choose?
Tom Witzig, MD, Mayo Clinic Rochester, Rochester, MN
12 September, 2020
SINE inhibitors: Selinexor
John Kuruvilla, MD, FRCPC, The Princess Margaret Cancer Centre, Toronto, ON
12 September, 2020
Tafasitamab (MOR208) in DLBCL
Gilles Salles, MD, PhD, South Lyon Hospital, Lyon, France
12 September, 2020
Previous session View all sessions Next session

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals